| # | Title | Journal | Year | Citations |
|---|
| 1 | Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations | Prostate | 1983 | 974 |
| 2 | Family history and the risk of prostate cancer | Prostate | 1990 | 609 |
| 3 | Molecular characterization of human prostate carcinoma cell lines | Prostate | 2003 | 555 |
| 4 | The zonal anatomy of the prostate | Prostate | 1981 | 521 |
| 5 | Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer | Prostate | 2004 | 475 |
| 6 | Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma | Prostate | 2000 | 465 |
| 7 | Etiology and disease process of benign prostatic hyperplasia | Prostate | 1989 | 453 |
| 8 | Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation | Prostate | 1993 | 407 |
| 9 | Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model | Prostate | 2003 | 402 |
| 10 | The TNM classification of prostate cancer | Prostate | 1992 | 383 |
| 11 | Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment | Prostate | 1999 | 382 |
| 12 | Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers | Prostate | 1986 | 367 |
| 13 | PC3 is a cell line characteristic of prostatic small cell carcinoma | Prostate | 2011 | 365 |
| 14 | Distribution of metastatic sites in patients with prostate cancer: A population‐based analysis | Prostate | 2014 | 352 |
| 15 | Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: A stem cell model | Prostate | 1996 | 346 |
| 16 | Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen | Prostate | 1996 | 337 |
| 17 | Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement | Prostate | 1987 | 330 |
| 18 | LNCaP progression model of human prostate cancer: Androgen-independence and osseous metastasis | Prostate | 2000 | 328 |
| 19 | Antagonistic effect of androgen on prostatic cell death | Prostate | 1984 | 327 |
| 20 | Radiation therapy for carcinoma of the prostate | Prostate | 1981 | 324 |
| 21 | The prostate: An increasing medical problem | Prostate | 1990 | 321 |
| 22 | Prostate antigen: A new potential marker for prostatic cancer | Prostate | 1981 | 319 |
| 23 | Increased Nox1 and hydrogen peroxide in prostate cancer | Prostate | 2005 | 309 |
| 24 | New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens | Prostate | 1983 | 305 |
| 25 | Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients | Prostate | 1996 | 294 |
| 26 | Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo | Prostate | 2001 | 292 |
| 27 | Neuroendocrine differentiation in prostatic carcinoma | Prostate | 1999 | 289 |
| 28 | Serum miRNA‐21: Elevated levels in patients with metastatic hormone‐refractory prostate cancer and potential predictive factor for the efficacy of docetaxel‐based chemotherapy | Prostate | 2011 | 287 |
| 29 | High‐grade prostate cancer is associated with low serum testosterone levels | Prostate | 2001 | 280 |
| 30 | Androgen deprivation therapy for prostate cancer: Current status and future prospects | Prostate | 2004 | 279 |
| 31 | p53 oncogene mutations in three human prostate cancer cell lines | Prostate | 1993 | 276 |
| 32 | Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer | Prostate | 2011 | 273 |
| 33 | Structural heterogeneity and protein composition of exosome‐like vesicles (prostasomes) in human semen | Prostate | 2009 | 271 |
| 34 | Regulation of prostatic growth and function by peptide growth factors | Prostate | 1996 | 269 |
| 35 | Transforming growth factor β1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer | Prostate | 1998 | 269 |
| 36 | Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled Trial | Prostate | 1999 | 262 |
| 37 | Androgen-repressed messages in the rat ventral prostate | Prostate | 1986 | 254 |
| 38 | Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration | Prostate | 1989 | 246 |
| 39 | Transrectal ultrasound in the diagnosis of prostate cancer: Location, echogenicity, histopathology, and staging | Prostate | 1985 | 243 |
| 40 | Targeting tumor metabolism with 2‐deoxyglucose in patients with castrate‐resistant prostate cancer and advanced malignancies | Prostate | 2010 | 241 |
| 41 | TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patients | Prostate | 2011 | 239 |
| 42 | Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer | Prostate | 1999 | 236 |
| 43 | Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer | Prostate | 2010 | 233 |
| 44 | The proliferative function of basal cells in the normal and hyperplastic human prostate | Prostate | 1994 | 231 |
| 45 | Overexpression of the EphA2 tyrosine kinase in prostate cancer | Prostate | 1999 | 230 |
| 46 | CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12 | Prostate | 2006 | 229 |
| 47 | Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway | Prostate | 2000 | 228 |
| 48 | Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis | Prostate | 2009 | 227 |
| 49 | Proteomic analysis of human prostasomes | Prostate | 2003 | 226 |
| 50 | Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion | Prostate | 2006 | 225 |
